Non Small Cell Lung Cancer Pipeline Insight
DelveInsight’s, Non-Small-Cell Lung cancer (NSCLC) - Pipeline Insight, 2023,” report provides comprehensive insights about 135+ companies and 150+ pipeline drugs in Non-Small-Cell Lung cancer (NSCLC) pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
- Global coverage
Non-Small-Cell Lung cancer (NSCLC) Understanding
Non-Small-Cell Lung cancer (NSCLC): Overview
Non-small-cell lung cancer (NSCLC) is any type of epithelial lung cancer other than small-cell lung cancer (SCLC) and accounts for about 85% of all lung cancers. There are three kinds of NSCLC tumors: a) Adenocancer starts in cells inside air sacs that make mucus and other substances, often in the outer parts of your lungs. It's the most common kind of lung cancer among both smokers and nonsmokers and people under 45. It often grows more slowly than other lung cancers. b) Squamous cell lung cancer starts in cells that line the inner airways of the lungs. About a quarter of lung cancers are this kind. c) Large cell (undifferentiated) cancer grows and spreads more quickly. That can make it tougher to treat. It's about 10% of lung cancers. An effective treatment for non-small cell adenocancer depends on the cancer’s stage. Surgery to remove all or only part of the lung is usually required if the cancer hasn’t spread.
"Non-Small-Cell Lung cancer (NSCLC) - Pipeline Insight, 2023" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Non-Small-Cell Lung cancer (NSCLC) pipeline landscape is provided which includes the disease overview and Non-Small-Cell Lung cancer (NSCLC) treatment guidelines. The assessment part of the report embraces, in depth Non-Small-Cell Lung cancer (NSCLC) commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Non-Small-Cell Lung cancer (NSCLC) collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
- The companies and academics are working to assess challenges and seek opportunities that could influence Non-Small-Cell Lung cancer (NSCLC) R&D. The therapies under development are focused on novel approaches to treat/improve Non-Small-Cell Lung cancer (NSCLC).
- In May 2022, BridgeBio Pharma and Bristol Myers Squibb (BMS) have entered an exclusive licence agreement for developing and marketing BBP-398 in oncology. An inhibitor of SHP2, BBP-398 was created through a partnership with the Therapeutics Discovery division of The University of Texas MD Anderson Cancer Center, US. Under the deal, BMS will make upfront and milestone payments of up to $905m to BridgeBio.
Non-Small-Cell Lung cancer (NSCLC) Drug Chapters
This segment of the Non-Small-Cell Lung cancer (NSCLC) report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Non-Small-Cell Lung cancer (NSCLC) Drugs
Datopotamab deruxtecan: Daiichi Sankyo
Datopotamab deruxtecan (Dato-DXd) is an investigational TROP2 directed ADC. Designed using Daiichi Sankyo’s proprietary DXd ADC technology, datopotamab deruxtecan is one of three leading ADCs in the oncology pipeline of Daiichi Sankyo, and one of the most advanced programs in AstraZeneca’s ADC scientific platform. Datopotamab deruxtecan is comprised of a humanized anti-TROP2 IgG13 monoclonal antibody, developed in collaboration with Sapporo Medical University, attached to a number of topoisomerase I inhibitor payloads, an exatecan derivative, via tetrapeptide-based cleavable linkers.
JDQ443, an investigational selective, covalent, and orally bioavailable KRASG12C inhibitor, shows 57% confirmed ORR at recommended dose of 200 mg twice daily in Phase Ib study in patients with advanced non-small cell lung cancer (NSCLC).
MRTX849: Mirati Therapeutics
Adagrasib (MRTX849) is an investigational, highly selective, and potent oral small-molecule inhibitor of KRASG12C that is optimized to sustain target inhibition, an attribute that could be important to treat KRASG12C-mutated cancers, as the KRASG12C protein regenerates every 24–48 hours. Adagrasib is being evaluated as monotherapy and in combination with other anti-cancer therapies in patients with advanced KRASG12C-mutated solid tumors, including NSCLC, colorectal cancer and pancreatic cancer.
INBRX-106 is a hexavalent product candidate agonist of OX40. OX40 is a co-stimulatory receptor expressed on immune cells that is enriched in the tumor microenvironment. OX40 ligand is a trimeric protein that activates OX40 signaling through clustering. INBRX-106 was engineered to bind and cluster six OX40 receptors and has been shown preclinically to significantly outperform bivalent antibodies in co-stimulatory capacity and anti-tumor activity.
Further product details are provided in the report……..
Non-Small-Cell Lung cancer (NSCLC): Therapeutic Assessment
This segment of the report provides insights about the Non-Small-Cell Lung cancer (NSCLC) drugs segregated based on following parameters that define the scope of the report, such as:
Major Players in Non-Small-Cell Lung cancer (NSCLC)
There are approx. 135+ key companies which are developing the therapies for Non-Small-Cell Lung cancer (NSCLC). The companies which have their Non-Small-Cell Lung cancer (NSCLC) drug candidates in the most advanced stage, i.e. Phase III include Daiichi Sankyo.
DelveInsight’s report covers around 150+ products under different phases of clinical development like
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
Route of Administration
Non-Small-Cell Lung cancer (NSCLC) pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
Products have been categorized under various Molecule types such as
- Antisense oligonucleotide
- Gene therapy
- Small Molecule
Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.
Non-Small-Cell Lung cancer (NSCLC): Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Non-Small-Cell Lung cancer (NSCLC) therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Non-Small-Cell Lung cancer (NSCLC) drugs.
Non-Small-Cell Lung cancer (NSCLC) Report Insights
- Non-Small-Cell Lung cancer (NSCLC) Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
Non-Small-Cell Lung cancer (NSCLC) Report Assessment
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Treatment Scenario and Emerging Therapies:
- How many companies are developing Non-Small-Cell Lung cancer (NSCLC) drugs?
- How many Non-Small-Cell Lung cancer (NSCLC) drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Non-Small-Cell Lung cancer (NSCLC)?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Non-Small-Cell Lung cancer (NSCLC) therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Non-Small-Cell Lung cancer (NSCLC) and their status?
- What are the key designations that have been granted to the emerging drugs?